Incanthera PLC Directors Dealings (8072V)
19 Aprile 2021 - 08:00AM
UK Regulatory
TIDMINC
RNS Number : 8072V
Incanthera PLC
19 April 2021
19 April 2021
Incanthera plc
("Incanthera" or the "Company")
Directors dealings
Incanthera plc (AQSE: INC), the specialist oncology company
focused on innovative technologies in oncology and dermatology
announces the purchase of shares in the Company by Directors of the
Board and Senior Management Team (the "Transactions").
The Transactions, recorded on 15 April 2021, on AQSE Growth
Market, are as follows:
Employee Company Position Transaction Volume Purchase Price
Tim McCarthy Chairman 49,382 13.50p
Simon Ward CEO 51,593 13.50p
Pawel Zolnierzyck COO 11,307
13.20p
Laura Brogden CFO 15,057 13.15p
Suzanne Brocks Head of Communications 50,000 13.00p
Total Shareholdings following the Transactions:
Employee Company Position Total Shareholding % of Share
Capital
Tim McCarthy Chairman 3,931,646 5.31%
Simon Ward CEO 2,704,199 3.65%
Pawel Zolnierzyck COO 669,544
0.90%
Laura Brogden CFO 46,034 0.06%
Suzanne Brocks Head of Communications 325,594 0.44%
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014 (which
forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).
For further enquiries:
Incanthera plc
www.incanthera.com
Tim McCarthy, Chairman
tim.mccarthy@incanthera.com +44 (0) 7831 675747
Simon Ward, Chief Executive Officer
simon.ward@incanthera.com +44 (0) 7747 625506
Suzanne Brocks, Head of Communications
suzanne.brocks@incanthera.com +44 (0) 7776 234600
Aquis Exchange Corporate Adviser:
Cairn Financial Advisers LLP
Jo Turner/James Lewis/Mark Rogers +44 (0) 20 7213 0880
Broker:
Stanford Capital Partners Ltd
Patrick Claridge/Tom Price/John Howes/Bob
Pountney +44 (0) 20 3815 8880
Notes to Editors
Incanthera is a specialist oncology company focused on
transforming cancer treatment by creating environments in which
cancer cannot survive. It seeks to identify and develop innovative
solutions to current clinical, commercially relevant unmet needs,
utilising new technology from leading academic institutions.
The Company's current lead product and focus is Sol, a
potentially innovative topical product for the treatment of solar
keratosis and the prevention of skin cancers. This has achieved
proof of concept and the Company is now focussed upon delivering
Sol to a commercial partner.
The Company originated from the Institute of Cancer Therapeutics
("ICT") at the University of Bradford and has acquired and
developed a portfolio of specific cancer-targeting therapeutics
through a Pipeline Agreement with the ICT and other corporate
acquisitions.
Incanthera's strategy is to develop each candidate in the
portfolio from initial acquisition or discovery to securing its
future through commercially valuable partnerships at the earliest
opportunity in its development pathway.
For more information on the Company please visit:
www.incanthera.com
Notification and public disclosure of transactions by persons
discharging managerial responsibilities/ person closely associated
with them.
1. Details of the person discharging managerial responsibilities/person
closely associated
Name
1. Tim McCarthy Chairman
2. Simon Ward CEO
3. Pawel Zolnierczyk PDMR
4. Laura Brogden PDMR
5. Suzanne Brocks PDMR
------------------------------- ----------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------
a) Position/status As above
------------------------------- ----------------------------------------
b) Initial notification/Amendment Initial Notification
------------------------------- ----------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Incanthera plc
------------------------------- ----------------------------------------
b) LEI 2138002HEV4UFBOEXQ97
------------------------------- ----------------------------------------
4. Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-------------------------------------------------------------------------
a) Description of the financial Ordinary Shares of 0.02p
instrument
------------------------------- ----------------------------------------
b) Identification code GB00BGL7YW15
------------------------------- ----------------------------------------
c) Nature of the transactions Purchase of Ordinary Shares
------------------------------- ----------------------------------------
d) Volumes and Prices Volume Price
1. 49,382 13.50p
-------
2. 51,593 13.50p
-------
3. 11,307 13.20p
-------
4. 15,057 13.15p
-------
5. 50,000 13.00p
-------
------------------------------- ----------------------------------------
e) Aggregated information Volume Prices
- Aggregated volume 177,339 13.00-13.50p
- Price -------------
------------------------------- ----------------------------------------
f) Date of the transactions 15 April 2021
------------------------------- ----------------------------------------
f) Place of the transactions AQSE Growth Market, UK
------------------------------- ----------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXDKFBPFBKDFQD
(END) Dow Jones Newswires
April 19, 2021 02:00 ET (06:00 GMT)
Grafico Azioni Incanthera (AQSE:INC)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Incanthera (AQSE:INC)
Storico
Da Mar 2023 a Mar 2024